Apellis Pharmaceuticals Revenue and Competitors

Claim your profile

Crestwood, KY USA



Total Funding



Estimated Revenue & Valuation

  • Apellis Pharmaceuticals's estimated annual revenue is currently $256.3M per year.(i)
  • Apellis Pharmaceuticals received $60.0M in venture funding in August 2017.
  • Apellis Pharmaceuticals's estimated revenue per employee is $305,083
  • Apellis Pharmaceuticals's total funding is $168.5M.
  • Apellis Pharmaceuticals's current valuation is $3.9B. (January 2022)

Employee Data

  • Apellis Pharmaceuticals has 840 Employees.(i)
  • Apellis Pharmaceuticals grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Apellis Pharmaceuticals News

2022-04-20 - Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $68 From $65, Maintains Outperform Rating

Technical analysis trends APELLIS PHARMACEUTICALS, INC. Short Term, Mid-Term, Long Term. Trends, Bullish, Bullish, Neutral...

2022-04-19 - Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives ...

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of...

2022-04-19 - Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Profit Outlook

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of...

2021-10-15 - Swedish Orphan Biovitrum : Aspaveli® (pegcetacoplan) receives positive CHMP opinion for treatment of PNH

Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announce today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Aspa ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Apellis Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2014-12-03$33.0MUndisclosedMorningside VenturesArticle
2016-02-15$47.0MDCormorant Asset ManagementArticle
2017-08-11$60.0MESectoral Asset ManagementArticle